Grifols acquires Novartis’ former industrial complex of 31,000 square meters in Parets del Valles, Barcelona

The company moves forward with its 400 million euro investment plan to expand production and guarantee future growth

Barcelona, January 17, 2008- Grifols, a holding company specialized in the pharmaceutical-hospital sector and fourth in the world in the production of plasma derivatives, acquired the industrial complex adjacent to the facilities of its Biomat S.A. company in Parets del Vallès. According to J. I. Twose, Vice President of production at Grifols, “this acquisition forms part of the investment plan which amounts to a total of 400 million euros. This plan was recently approved with the objective of increasing our production capacity for plasma derivatives and guaranteeing the company’s growth.”

The acquired industrial complex covers a surface area of 31,000 square meters, of which 6,000 m2 is a parcel of land on which, said Twose, “we are looking into building a new plasma fractionation plant which will allow us to double our current capacity in Spain. Our intention is to be able to begin production with all the required international permits and licenses in 2013.”

There are several different buildings used for various purposes on the remaining surface area, one of which is a totally automated storage silo for 8,200 pallets, very similar to the one pertaining to the group in a nearby location. “As of April, these buildings which have a total of 19,000 square meters will be in our possession so that we can remodel and adapt them to our needs,” said Twose. “This is where the central headquarters of group’s logistics will be located. We hope to move them in the final quarter of 2008” affirmed Twose.

This acquisition was brokered by the real estate firm Jordà & Guasch.

New facilities to manufacture a new plasma derivative

In addition to acquiring these installations, Grifols is in the final stage of finishing another two buildings in the same industrial area which will be in use by the second quarter of 2008.

The first of these is more than 3,500 meters squared on two levels, and will be the future home of General Management, the Technical Area, Administration and part of the Hospital division’s storage area for raw materials. According to Vice President Twose, “getting this new building up and running is vitally important to free up space which is being occupied in the Bioscience factory, where we have already begun working on building a production plant for the new plasma derivative fibrin glue, a biological glue for surgical use.
The protocol for clinical assays for this new product is being presented to the health authorities in Canada, Spain and the UK for their approval, after which it will be presented in the United States. Grifols expects to begin these clinical assays sometime this year and to market the product in 2012.

The second building is 6,000 square meters and has two floors. J. I. Twose indicated that “Grifols Engineering will have new facilities on the first floor to carry out its engineering and also some general services. On the second floor, various corporate offices from different areas will be relocated to optimize resources and improve the company’s overall efficiency.”

About Grifols

Grifols is a Spanish holding company specialized in the pharmaceutical-hospital sector and is present in more than 90 countries. Since 2006, the company has been listed on the Spanish Continuous Market and forms part of the Ibex-35. Currently it is the first company in the European sector in plasma derivatives and the fourth in production worldwide. In upcoming years, the company will strengthen its leadership in the industry as a vertically integrated company, thanks to recent investments and those which will be carried out in 2008-2012, representing 400 million euros. In terms of raw materials, Grifols has ensured its plasma supply with 77 plasmapheresis centers in the United States and in terms of fractionation, its plants in Barcelona (Spain) and Los Angeles (United States) will allow the company to respond to the growing market demand. Nevertheless, the company is preparing for sustained growth in the following 8-10 years and has launched an ambitious investment plan.